OKYO Pharma (NASDAQ:OKYO) & Kyverna Therapeutics (NASDAQ:KYTX) Head-To-Head Survey

Kyverna Therapeutics (NASDAQ:KYTX) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Profitability

This table compares Kyverna Therapeutics and OKYO Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-51.12%	-37.91%
OKYO Pharma	N/A	N/A	N/A

Risk and Volatility

Kyverna Therapeutics has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.32, indicating that its share price is 132% less volatile than the S&P 500.

Valuation and Earnings

This table compares Kyverna Therapeutics and OKYO Pharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	$7.03 million	12.17	-$60.37 million	($3.47)	-0.57
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A

OKYO Pharma has lower revenue, but higher earnings than Kyverna Therapeutics.

Insider and Institutional Ownership

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Kyverna Therapeutics and OKYO Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	0	1	5	1	3.00
OKYO Pharma	0	0	1	0	3.00

Kyverna Therapeutics presently has a consensus target price of $18.33, suggesting a potential upside of 825.93%. OKYO Pharma has a consensus target price of $7.00, suggesting a potential upside of 514.04%. Given Kyverna Therapeutics’ higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than OKYO Pharma.

Summary

Kyverna Therapeutics beats OKYO Pharma on 6 of the 10 factors compared between the two stocks.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.